MGMyrte Gorris

Myrte Gorris

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Myrte Gorris has a total of 124 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Small and Stable Pancreatic Cysts Are Reassuring During Surveillance: Results From the PACYFIC Trial

    by Iris J. M. Levink, Marloes L. J. A. Sprij, Brechtje D. M. Koopmann, Jihane Meziani, Sanne Jaarsma, Priscilla A. van Riet, Kasper A. Overbeek, Myrte Gorris, Rogier P. Voermans, Jeanin E. van Hooft, et al.

    Background: Pancreatic cysts are increasingly discovered on imaging studies performed for unrelated conditions. Currently, surveillance of these lesions poses a substantial burden on patients, and health care recourses. We hypothesized that individuals with small and stable cysts have a diminutive risk of progressing to high‐grade dysplasia (HGD) or pancreatic cancer (PC) that is similar to that in the general population.Methods: This nested PACYFIC‐study is a collaboration among 44 centers in Europe and Northern‐America, and investigates the risk of HGD and PC for different cyst sizes and growth rates in participants without baseline worrisome features (WF) or high‐risk stigmata (HRS).Results: Of the 2369 PACYFIC participants, 975 met the inclusion criteria, with a mean age of 67 years (SD 13) and 65% being female. Of these, 438 individuals (45%) had a baseline small cyst size (< 15 mm), and 885 (91%) individuals had a slow growth rate (< 2.5 mm/year). During a median follow‐up of 45 months (IQR 27), 20 individuals (2.1%) developed HGD, or PC. Individuals with small cysts had a 1.5‐fold lower risk of developing WF or HRS (hazard ratio [HR] 0.7 [0.5–1.0], p = 0.03) than those with larger cysts but a similar risk of developing HGD or PC (p > 0.05). Slow growth was protective against the development of WF or HRS (HR 0.4 [0.2–0.6], p < 0.001) and HGD or PC (HR 0.04 [95% CI 0.02–0.12], p < 0.001). Individuals with small, stable sized cysts without baseline WF or HRS did not have a higher risk of HGD or PC than the general population (standardized incidence ratio [SIR] 1.13 [95% CI 0.01–6.30]).Conclusion: Cyst size < 15 mm and growth rate < 2.5 mm/year appear to be “reassuring” features associated with a negligible risk of developing WF or HRS and HGD or PC. For cysts with these characteristics—and without baseline WF or HRS—less intensive surveillance (than currently recommended) or even cessation may be appropriate.


  • Impact of Adjuvant Chemotherapy on Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Results From an International Multicenter Study

    by Joseph R Habib, Benedict Kinny-Köster, Ammar A Javed, Poitr Zelga, Lily V Saadat, Rachel C Kim, Myrte Gorris, Valentina Allegrini, Shuichi Watanabe, Jeremy Sharib, et al.

    PURPOSE: The benefit of adjuvant therapy for intraductal papillary mucinous neoplasm (IPMN)-derived pancreatic ductal adenocarcinoma (PDAC) remains unclear because of severely limited evidence. Although biologically distinct entities, adjuvant therapy practices for IPMN-derived PDAC are largely founded on pancreatic intraepithelial neoplasia-derived PDAC. We aimed to evaluate the role of adjuvant chemotherapy in IPMN-derived PDAC. METHODS: This international multicenter retrospective cohort study (2005-2018) was conceived at the Verona Evidence-Based Medicine meeting. Cox regressions were performed to identify risk-adjusted hazard ratios (HR) associated with overall survival (OS). Kaplan-Meier curves and log-rank tests were employed for survival analysis. Logistic regression was performed to identify factors motivating adjuvant chemotherapy administration. A decision tree was proposed and categorized patients into overtreated, undertreated, and optimally treated cohorts. RESULTS: In 1,031 patients from 16 centers, nodal disease (HR, 2.88, P < .001) and elevated (≥37 to P = .006) or markedly elevated (≥200 µ/mL, HR, 2.53, P < .001) carbohydrate antigen 19-9 (CA19-9) were associated with worse OS. Node-positive patients with elevated CA19-9 had an associated 34.4-month improvement in median OS ( P = .047) after adjuvant chemotherapy while those with positive nodes and markedly elevated CA19-9 had an associated 12.6-month survival benefit ( P < .001). Node-negative patients, regardless of CA19-9, did not have an associated benefit from adjuvant chemotherapy (all P > .05). Based on this model, we observed undertreatment in 18.1% and overtreatment in 61.2% of patients. Factors associated with chemotherapy administration included younger age, R1-margin, poorer differentiation, and nodal disease. CONCLUSION: Almost half of patients with resected IPMN-derived PDAC may be overtreated or undertreated. In patients with node-negative disease or normal CA19-9, adjuvant chemotherapy is not associated with a survival benefit, whereas those with node-positive disease and elevated CA19-9 have an associated benefit from adjuvant chemotherapy. A decision tree was proposed. Randomized controlled trials are needed for validation.


  • Open Access

    Comparison of two intraductal brush cytology devices for suspected malignant biliary strictures: randomized controlled trial

    by Myrte Gorris, Nadine C. M. van Huijgevoort, Paul Fockens, Sybren L. Meijer, Joanne Verheij, Rogier P. Voermans, Roy L. J. van Wanrooij, Selma J. Lekkerkerker, Jeanin E. van Hooft

    Background: Endoscopic retrograde cholangiopancreatography (ERCP) with biliary brush cytology is commonly used to diagnose malignant pancreatobiliary strictures. This trial compared the sensitivity of two intraductal brush cytology devices. Methods: A randomized controlled trial in which consecutive patients with suspected malignant, extrahepatic biliary strictures were randomized (1:1) to a dense or conventional brush cytology device. Primary endpoint was sensitivity. Interim analysis was conducted after 50% of the patients completed follow-up. Results were interpreted by a data safety monitoring board. Results: Between June 2016 and June 2021, 64 patients were randomized to the dense (27 patients, 42%) or conventional brush (37 patients, 58%). Malignancy was diagnosed in 60 patients (94%) and benign disease in 4 patients (6%). Diagnoses were confirmed by histopathology in 34 patients (53%), cytopathology in 24 patients (38%), and clinical or radiological follow up in 6 patients (9%). Sensitivity of the dense brush was 50%, compared to 44% for the conventional brush (p = 0·785). Discussion: The results of this randomized controlled trial showed that the sensitivity of a dense brush is not superior to a conventional brush for diagnosing malignant extrahepatic pancreatobiliary strictures. This trial was prematurely ended for reasons of futility. Trial registration: Netherlands Trial Register number; NTR5458.


  • Open Access

    Validation of combined carcinoembryonic antigen and glucose testing in pancreatic cyst fluid to differentiate mucinous from non-mucinous cysts

    by Myrte Gorris, Frederike Dijk, Arantza Farina, Johannes B. Halfwerk, Gerrit K. Hooijer, Selma J. Lekkerkerker, Rogier P. Voermans, Mattheus C. Wielenga, Marc G. Besselink, Jeanin E. van Hooft

    Background: More accurate diagnosis of mucinous cysts will reduce the risk of unnecessary pancreatic surgery. Carcinoembryonic antigen (CEA) and glucose in pancreatic cyst fluid (PCF) can differentiate mucinous from non-mucinous pancreatic cystic neoplasms (PCN). The current study assessed the value of combined CEA and glucose testing in PCF. Methods: Cross-sectional validation study including prospectively collected PCF from patients undergoing endoscopic ultrasonography-guided fine-needle aspiration (EUS-FNA) and pancreatic surgery. We performed laboratory measurements for CEA and glucose and measured glucose levels by a hand glucometer. Primary outcome was diagnostic accuracy evaluated by receiver operator curves (ROC), sensitivity, specificity, positive, and negative predictive value (PPV, NPV). Results: Overall, PCF was collected from 63 patients, including 33 (52%) with mucinous and 30 (48%) with non-mucinous PCN. Histopathology (n = 36; 57%), cytopathology (n = 2; 3%), or clinical and/or radiological diagnosis (n = 25; 40%) was used as reference standard. Combined CEA (cut-off ≥ 192 ng/ml) and laboratory glucose testing (cut-off ≤ 50 mg/dL) reached 92% specificity and 48% sensitivity, whereas either positive CEA (cut-off ≥ 20 ng/ml) or glucose testing (cut-off ≤ 50 mg/dL) showed 97% sensitivity and 50% specificity. Sensitivity and specificity were 80% and 68% for CEA ≥ 20 ng/mL versus 50% and 93% for CEA ≥ 192 ng/mL (the conventional cut-off level). Laboratory and glucometer glucose both reached 100% sensitivity and 60% and 45% specificity, respectively. None of the biomarkers and cut-offs reached a PPV exceeding 90%, whereas both glucose measurements had a NPV of 100% (i.e., high glucose excludes a mucinous cyst). Conclusion: Combined CEA and glucose testing in PCF reached high specificity and sensitivity for differentiating mucinous from non-mucinous PCN. Glucose testing, whether alone or combined with the new CEA cut-off (≥ 20 ng/mL), reached > 95% sensitivity for mucinous cysts, whereas only glucose reached a NPV > 95%. Graphical


  • Open Access

    Comparing Survival after Resection of Pancreatic Cancer with and without Pancreatic Cysts: Nationwide Registry-Based Study

    by Myrte Gorris, Nadine C. M. van Huijgevoort, Arantza Farina, Lodewijk A. A. Brosens, Hjalmar C. van Santvoort, Bas Groot Koerkamp, Marco J. Bruno, Marc G. Besselink, Jeanin E. van Hooft

    Background: Outcome after resection of pancreatic ductal adenocarcinoma associated with pancreatic cystic neoplasms (PCN-PDAC) might differ from PDAC not associated with PCN. This nationwide, registry-based study aimed to compare the overall survival (OS) in these patients. Methods: Data from consecutive patients after pancreatic resection for PDAC between 2013 and 2018 were matched with the corresponding pathology reports. Primary outcome was OS for PCN-PDAC and PDAC including 1-year and 5-year OS. Cox regression analysis was used to correct for prognostic factors (e.g., pT-stage, pN-stage, and vascular invasion). Results: In total, 1994 patients underwent resection for PDAC including 233 (12%) with PCN-PDAC. Median estimated OS was better in patients with PCN-PDAC (34.5 months [95%CI 25.6 to 43.5]) as compared to PDAC not associated with PCN (18.2 months [95%CI 17.3 to 19.2]; hazard ratio 0.53 [95%CI 0.44–0.63]; p < 0.001). The difference in OS remained after correction for prognostic factors (adjusted hazard ratio 1.58 [95%CI 1.32−1.90]; p < 0.001). Conclusions: This nationwide registry-based study showed that 12% of resected PDAC were PCN-associated. Patients with PCN-PDAC had better OS as compared to PDAC not associated with PCN.


  • EP1156: ARE BIOMARKERS IN PANCREATIC JUICE USEFUL TO DIFFERENTIATE BETWEEN CHRONIC PANCREATITIS AND IPMN WITH MAIN DUCT INVOLVEMENT?

    by Sanne A. Hoogenboom, Myrte Gorris, Michiel de Maaker, Hans Halfwerk, Selma Lekkerkerker, Mattheus C. Wielenga, Marc G. Besselink, Jeanin E. Van Hooft, Frederike Dijk

  • Open Access

    Does same session EUS-guided tissue acquisition and ERCP increase the risk of pancreatitis in patients with malignant distal biliary obstruction?

    by Myrte Gorris, Noortje P. van der Valk, Paul Fockens, Maarten A. Jacobs, Nahid S.M. Montazeri, Rogier P. Voermans, Mattheus C. Wielenga, Jeanin E. van Hooft, Roy L. van Wanrooij


  • COMPARISON OF TWO INTRADUCTAL BRUSH CYTOLOGY DEVICES FOR SUSPECTED MALIGNANT BILIARY STRICTURES: INTERIM-ANALYSIS OF A RANDOMIZED CONTROLLED TRIAL

    by M. Gorris, N. van Huijgevoort, P. Fockens, S. Lekkerkerker, S. Meijer, J. Verheij, R. Voermans, R. van Wanrooij, J. van Hooft

    Aims Endoscopic retrograde cholangiopancreatography (ERCP) with brush cytology is commonly used to obtain tissue diagnosis of suspected malignant pancreatobiliary strictures. We aimed to compare the sensitivity of two intraductal brush cytology devices in these patients. Methods We performed a randomized controlled trial in consecutive patients with suspected malignant, non-hilar biliary strictures who underwent ERCP with concomitant sphincterotomy. Patients were randomly assigned (1:1) to either the Infinity​ or the RX cytology​ brush. Histopathological results, cytopathology results or clinical and/or radiological follow-up were used as reference standard. Primary endpoint was sensitivity, defined as brush cytology specimen showing at least suspicion of malignancy (Bethesda≥4) in patients with malignant diagnosis. Secondary endpoints were diagnostic performance and adverse events. Interim analysis was conducted after 50% of the patients completed follow-up. Results We screened 172 patients and could randomize 56 patients to the Infinity​ brush (24 patients, 43%) or to the RX cytology​ brush (32 patients, 57%) between June 2016 and April 2020. Sensitivity of the Infinity​ brush and RX cytology​ brush were 50% and 45%, respectively. Diagnosis was confirmed by histopathology (n=24, 43%), cytopathology (n=26, 46%), and clinical or radiological follow up (n=6, 11%) and revealed malignancy in 52 patients (93%) and benign disease in 4 patients (7%). No differences in diagnostic performance or adverse events were observed. The study was ended prematurely because of futility. Conclusions The results of this study showed at the interim analysis that the sensitivity of the Infinity​ brush is not superior to RX cytology​ brush for diagnosing malignant pancreatobiliary strictures. Publication Date: 14 April 2022 (online) © 2022. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

  • Open Access

    Sensitivity of CT, MRI, and EUS-FNA/B in the preoperative workup of histologically proven left-sided pancreatic lesions

    by Myrte Gorris, Quisette P. Janssen, Marc G. Besselink, Bram L.J. van Den Broek, Casper H.J. van Eijck, Marjon J. van Gils, Bas Groot Koerkamp, Femke Struik, Lydi M.J.W. van Driel, Jeanin E. van Hooft


  • Open Access

    Treatment for chronic hepatitis E virus infection: A systematic review and meta‐analysis

    by Myrte Gorris, Bernice M. van der Lecq, Karel J. van Erpecum, Joep de Bruijne

    Hepatitis E virus infection can cause chronic hepatitis in immunocompromised patients with significant chance of progressive fibrosis and possibly cirrhosis. The aim of this systematic review was to summarize the efficacy and safety of the various treatment options for chronic hepatitis E. We performed a systematic literature search. The primary outcome measure was a sustained virological response (SVR). Secondary end points were rapid virological response (RVR), relapse rates, side effects and adverse events. Forty‐four articles were included with a total of 582 patients. Reduction of immunosuppressive medication induced viral clearance in 55/174 (32%) of the patients. Meta‐analysis of 395 patients showed a pooled SVR rate of 78% (95‐CI 72%–84%) after ribavirin treatment. Twenty‐five per cent of the patients obtained a RVR, whereas a relapse occurred in 18% of the patients. Anaemia during treatment led to dose reduction, use of erythropoietin and/or blood transfusion in 37% of the patients. A second treatment attempt with ribavirin led to a SVR in 39/51 (76%) of the patients. Pegylated interferon‐alpha was administered to 13 patients and SVR was obtained in 85%. Two patients (15%) suffered from acute transplant rejection during treatment with interferon. In conclusion, reduction of immunosuppressive medication and treatment with ribavirin is safe, generally well tolerated and induced viral clearance in 32% and 78% of patients, respectively. Therefore, ribavirin should be considered as first treatment step for chronic hepatitis E. Treatment with pegylated interferon‐alpha increases the risk of transplant rejection and should therefore be administered with great caution.